drugset / Trial / NCT05900531

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

NCT05900531

Phase 1 Completed 60 enrolled Kallyope Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.

Timeline

Start
2022-09-21
Primary completion
2023-05-03
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject K-757 Unknown Oral
Subject K-833 Unknown Oral
Subject Sitagliptin Small molecule Oral

Indications